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Abstract
Background:  Inflammatory cytokines may promote tumorigenesis. Macrophage migration
inhibitory factor (MIF) is a proinflammatory cytokine with regulatory properties over tumor
suppressor proteins involved in bladder cancer. We studied the development of bladder cancer in
wild type (WT) and MIF knockout (KO) mice given N-butyl-N-(4-hydroxybutyl)-nitrosamine
(BBN), a known carcinogen, to determine the role of MIF in bladder cancer initiation and
progression.
Methods: 5-month old male C57Bl/6 MIF WT and KO mice were treated with and without BBN.
Animals were sacrificed at intervals up to 23 weeks of treatment. Bladder tumor stage and grade
were evaluated by H&E. Immunohistochemical (IHC) analysis was performed for MIF and platelet/
endothelial cell adhesion molecule 1 (PECAM-1), a measure of vascularization. MIF mRNA was
analyzed by quantitative real-time polymerase chain reaction.
Results: Poorly differentiated carcinoma developed in all BBN treated mice by week 20. MIF WT
animals developed T2 disease, while KO animals developed only T1 disease. MIF IHC revealed
predominantly urothelial cytoplasmic staining in the WT control animals and a shift toward nuclear
staining in WT BBN treated animals. MIF mRNA levels were 3-fold higher in BBN treated animals
relative to controls when invasive cancer was present. PECAM-1 staining revealed significantly
more stromal vessels in the tumors in WT animals when compared to KOs.
Conclusion: Muscle invasive bladder cancer with increased stromal vascularity was associated
with increased MIF mRNA levels and nuclear redistribution. Consistently lower stage tumors were
seen in MIF KO compared to WT mice. These data suggest that MIF may play a role in the
progression to invasive bladder cancer.
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Background
Bladder cancer is a common urinary tract malignancy. In
2007 there will be an estimated 67,160 new cases with
13,750 deaths in the United States alone [1]. Stage at diag-
nosis is fundamental to outcome as 50% of patients with
muscle invasion have metastatic disease. Current thera-
pies for advanced disease are disappointing. Even with
aggressive surgical and medical treatment most patients
with advanced bladder cancer ultimately succumb to their
disease.
Recent research has suggested an important role for
inflammatory cytokines and chemokines in the develop-
ment of cancer. They may promote tumorigenesis by pro-
viding an environment that enhances cell proliferation,
survival and migration. Macrophage migration inhibitory
factor (MIF) is a proinflammatory cytokine that has regu-
latory properties over mediators such as p53 and the retin-
oblastoma protein (pRb) known to be involved in
invasive bladder cancer [2,3]. Overexpression of MIF has
been implicated in several cancers [4-6]. We studied the
effects of knocking out the gene for MIF (mif-/-) on the
development of bladder cancer in mice given N-butyl-N-
(4-hydroxybutyl)-nitrosamine (BBN).
Methods
Mice lacking MIF (MIF-KO) were generated by homolo-
gous recombination and backcrossed into a pure C57BL/
6 background (generation N8) [7]. Animals were bred and
maintained at the University of Connecticut Health
Center for Laboratory Animal Care under National Insti-
tutes of Health guidelines. All procedures were approved
by an institutional animal care committee. Fifty 5 month
old C57Bl/6 MIF-KO and WT mice were housed in a con-
trolled environment with a 12 hour light – 12 hour dark
cycle and provided food and water ad libitum. The exper-
imental group received BBN (TCI America, Portland, OR)
0.05% in water in brown bottles throughout. Two mice
from each group (WT control and treated, KO control and
treated) were euthanized by CO2 inhalation at 4, 8, 12, 16,
20 and 23 weeks. Bladders were harvested and inspected
for tumor prevalence. Half of each bladder, and tumor if
present, was used for pathologic evaluation and half for
analysis of mRNA.
Pathologic analysis
Bladder halves were placed in PBS/formaldehyde for 24
hours and then transferred to PBS. Bladder halves were
sagitally sectioned into 3 levels (inner, mid, outer) and
stained with H&E. Characteristics such as number of cell
layers, nuclear size, nuclear membrane irregularity, chro-
matin pattern, nuclear:cytoplasmic ratio, presence of
nucleoli and mitosis were evaluated in order to provide a
final diagnosis of (1) normal, (2) metaplasia, (3) atypia,
(4) carcinoma in situ (CIS) and (5) carcinoma. The term
carcinoma is applied to all cancers as lesions showed
mixed histology with both transitional and squamous ele-
ments. Tumor stage and grade are the most predictive var-
iables with regard to prognosis and these were the main
outcome metrics in our model. Invasion was diagnosed if
tumor cells were seen infiltrating the muscle layers of the
bladder. A single pathologist (P.H.) reviewed all slides in
a blinded fashion.
Immunohistochemistry (IHC)
IHC for MIF was performed in a standard method. Endog-
enous peroxidase activity was blocked by treatment with
3% H2O2 in PBS for 30 min. Non-specific staining was
blocked by incubation with Power Block™ Universal
Blocking agent (Biogenex, San Ramon, CA). Specimens
were rinsed in PBS. Tissue sections were stained with a
rabbit polyclonal anti-MIF antibody (Cell Sciences,
CPM300). Sections were incubated overnight at 4–8°C
(dilution 1:1000). Bound antibody was detected with a
secondary biotinylated anti-rabbit antibody for 30 min at
room temperature (1:200) and visualized using diami-
nobenzidine (DAB) as a chromogenic substrate according
to the manufacturer's instructions (Vector Labs, Burlin-
game, CA).
Sections were evaluated for degree of nuclear staining and
scored from 0–3 corresponding to negative, weak, inter-
mediate and strong staining respectively. Results were
quantified using an H-score as previously described [8].
Three fields were chosen representing areas of maximal
staining at 200× magnification. The total number of
nuclei and total number staining at each intensity were
counted. The average percentage positive for each group
was calculated. H-score was calculated as equal to (% of
cells stained at intensity 0 × 0) + (% of cells stained at
intensity 1 × 1) + (% of cells stained at intensity 2 × 2) +
(% of cells stained at intensity 3 × 3). This resulted in a
score between 0 and 300 where 300 is equal to 100% of
tumor cell nuclei staining strongly.
IHC for PECAM-1 was performed in a standard method.
Endogenous peroxidase activity was blocked by treatment
with 3% H2O2 for 10 min. Non-specific staining was
blocked by incubation with Power Block™ for 10 min. Tis-
sue sections were stained with a goat polyclonal anti-
PECAM antibody (Santa Cruz Biotechnology, M20 SC-
1506) at 1:500 dilution in PBS-BSA overnight at 4°C.
Bound anti-PECAM-1 antibody was detected with a sec-
ondary biotinylated horse-anti-goat antibody for 30 min
at room temperature (1:200) and visualized using DAB.
Microvessel density (MVD) was calculated by the Weidner
method [9]. Using light microscopy (200× field), tumors
were evaluated for associated angiogenesis. The region in
each specimen that represented the area of maximal activ-BMC Cancer 2007, 7:135 http://www.biomedcentral.com/1471-2407/7/135
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ity was then processed to capture the vascular structures
present with minimal background using Image Pro Plus
analytical software (Media Cybernetics, Silver Spring,
MD). Results were quantified and defined in terms of pix-
els/field.
Quantitative polymerase chain reaction for mRNA
Quantitative real time PCR (qPCR) was performed for
MIF and TNF-α mRNA with GAPDH as an internal con-
trol. Total RNA was extracted from bladder tissues with
TRIzol® Reagent (Invitrogen Life Technologies, Carlsbad,
CA) following the manufacturer's protocol. Total RNA
was converted to cDNA by ABI High Capacity cDNA
Archive Kit (Applied Biosystems, Foster City, CA) follow-
ing the manufacturer's protocol. qPCR was performed for
different gene expression in separate wells (singleplex
assay) of a 96-well plate in a reaction volume of 20 μl.
Three replicates of each sample were amplified using
Assays-on-Demand Gene Expression assay (Assay #
Mm01604696_g1 for MIF, Mm00443258_m1 for TNF
and Mm99999915_g1 for GAPDH) which contain prede-
signed, unlabeled gene-specific PCR primers and TaqMan
MGB FAM dye-labeled probe. The PCR reaction mixture
(including 2 × TaqMan Universal PCR Master Mix, 20 ×
Assays-on-Demand Gene Expression Assay Mix, 50 ng of
cDNA) was run in Applied Biosystems ABI Prism 7300
Sequence Detection System instrument utilizing universal
thermal cycling parameters. For genes for which the effi-
ciencies of target and endogenous control amplification
were approximately equal, the relative quantification
expression in a test sample to a reference calibrator sample
(ΔΔCt Method) was used for data analysis. For genes
which were not amplified with the same efficiency as the
endogenous control, The Relative Standard Curve method
in which target quantity is determined from the standard
curve and divided by the target quantity of the calibrator
was used.
Results
Pathology
All BBN treatment groups displayed equal evidence of
sub-mucosal inflammation and edema from the earliest
time point. Varying degrees of atypia and metaplasia were
noted through week 12 (Figure 1). Carcinoma, represent-
ing focal areas of CIS, was noted at 16 weeks in both WT
and KO mice. At 20 and 23 weeks specimens showed
poorly differentiated, high-grade, carcinoma in both gen-
otypes (Figure 1). Tumors were bulky, occupying the
majority of bladder lumens precluding precise assessment
of the number of tumors present per bladder. However,
stage and grade are the most important variables with
regard to prognosis in bladder cancer. Although no differ-
ence in grade was noted, BBN treated MIF KO bladders (n
= 3) had consistently lower tumor stage with no invasion
into muscle layers noted (T1). Muscle invasion (T2) was
present in all MIF WT bladders (n = 5) at 20–23 wks rep-
resenting a 100% discordance in phenotype. One MIF KO
mouse died prior to sacrifice at 22 weeks with cancer
noted but was excluded from analysis because necrolysis
prevented accurate tumor staging.
Immunohistochemistry
At early time points (4–16 wks) MIF was noted to be con-
stitutively expressed and localized to the urothelial layer
in the WT groups, which is in agreement with a prior
report [10]. No staining was seen in the KO mice. Staining
intensity revealed no pathologic difference between
groups treated with and without BBN including areas of
metaplasia and CIS. No change in cellular localization
was seen either. At 20 weeks when cancer was present,
increased intensity of MIF staining was noted in WT
treated specimens relative to earlier specimens and to WT
untreated specimens. WT control animals showed pre-
dominantly cytoplasmic staining with scant nuclear stain-
ing confined to the urothelial layer. BBN treated animals
showed intense cytoplasmic and nuclear staining in a
large proportion of tumor cells (Figure 2). Mean nuclear
H-scores for WT control and BBN-treated animals were
63.3 and 152 respectively (p = 0.2, based on the Wilcoxon
rank sum test of location difference).
PECAM-1 staining showed an increase in the number of
tumor associated vessels in the WT as compared to KO
animals (Figure 3). Mean MVD ± SE for the WT and KO
specimens were 11.7 × 106 ± 1.7 × 106 and 6.7 × 106 ± 1.0
× 106 respectively (p = 0.04, based on the two sample t-test
for difference in means).
mRNA expression
MIF mRNA levels were evaluated in bladders from WT
animals. The KO bladders had no evidence of MIF mRNA
expression by RT-PCR or protein by IHC. MIF mRNA lev-
els gradually increased in the treated animals versus con-
trols (Figure 4). By week 23 when invasive cancer was
present, the observed MIF mRNA level was 3-fold higher
in the BBN treated mice compared to controls. TNFα, a
marker of inflammation, was elevated equally in WT and
KO treated animals from the earliest time points.
To investigate the statistical significance of the treatment
effect we fit a linear regression model to the data. Residual
diagnostics for non-constant variance and non-normality
revealed no evidence of model inadequacy. We tested for
an overall treatment effect by performing a partial F-test
with p < .01, indicating a highly statistically significant
overall treatment effect.
Discussion
MIF is a widely expressed molecule first described for its
ability to inhibit the random migration of macrophages inBMC Cancer 2007, 7:135 http://www.biomedcentral.com/1471-2407/7/135
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vitro [11]. Its participation in the host response to inflam-
mation and defense is well established [12]. As a result of
its biological actions, MIF may prove to play an important
role in tumorigenesis. MIF activates the MAPK/ERK sign-
aling pathway, which regulates cellular proliferation and
survival. MIF has been reported to inhibit p53 tumor sup-
pressor activity via a COX-2/PGE2 dependant pathway
resulting in cell growth and preventing cell regulated
apoptosis [2,13]. It has also been reported to increase cyc-
lin D transcription leading to increased phosphorylation
of pRb resulting in cellular proliferation [3,14]. In addi-
tion, MIF has recently been shown to promote survival in
fibroblasts via a phosphoinositide-3-kinase (PI3K)/Akt
signaling pathway [15]. Recent publications have sug-
gested that MIF expression can lead to increased angiogen-
esis which is integral to cancer growth, invasion and
metastasis [16,17].
MIF has been implicated in prostate, lung and breast can-
cer with overexpression shown to correlate with tumor
grade/stage and prognosis [4-6]. Bladder epithelial cells
not only produce MIF but may also display upregulation
in response to diverse stimuli [10,18]. Recently, inhibi-
tion of MIF with hyaluronic acid, anti-MIF antibody or
MIF anti-sense, was shown to decrease in vitro bladder
cancer cell proliferation and cytokine expression [10].
Our results suggest that MIF may be involved in the pro-
gression of bladder cancer to muscle invasion. The
absence of MIF did not impair tumor development but
was associated with the absence of tumor invasion into
muscle. Muscle invasive disease was present in all WT ani-
mals and was associated with a notable increase in stro-
mal angiogenesis. At the time of muscle invasion MIF
mRNA levels were three-fold higher in the treated versus
control animals. In addition, a pattern of MIF protein
nuclear redistribution was noted. mRNA levels for TNFα,
another inflammatory mediator, were elevated equally in
both the WT and KO mice throughout the duration of the
study and pathologic evidence of inflammation (sub-
mucosal edema, inflammatory cell infiltrate) was equal as
well, suggesting no difference in exposure to metabolites
of BBN.
The mechanism by which MIF may facilitate invasion of
tumor cells is currently unknown. Cell lines have shown
an increased expression of matrix metalloproteases,
important in the breakdown of the extracellular matrix,
when exposed to recombinant MIF [19,20]. Cancer cells
have demonstrated an increase in invasive capacity when
exposed to recombinant MIF [16] or co-cultured with
macrophages leading to a TNF-α dependant increase in
MIF expression via an NFκ-B pathway [17]. Additionally,
H&E sections from representative time points for MIF WT and KO mice treated with BBN (+) Figure 1
H&E sections from representative time points for MIF WT and KO mice treated with BBN (+). Arrows denote; subepithelial 
inflammation (4 week) and squamous metaplasia (8 week). High grade carcinoma is present at 20 weeks. Arrowheads show 
muscle cells with (WT+) and without (KO+) invasive carcinoma.BMC Cancer 2007, 7:135 http://www.biomedcentral.com/1471-2407/7/135
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we have recently reported both in vitro and in vivo evidence
that MIF promotes bladder muscle cell death which could
facilitate tumor cell invasion [21].
Angiogenesis is recognized as an important step in tumor
invasion and metastasis. Proangiogenic factors have been
identified in bladder cancer and MVD has been shown to
be a prognostic indicator [22]. Many of the same studies
noted above also evaluated angiogenesis and were able to
show increased angiogenic properties related to the
expression of MIF. Ovarian and breast cancer cells had a
MIF-dependent increase in angiogenic factors when co-
cultured with macrophages [17]. In vivo studies utilizing
small interfering RNA (siRNA) transfected cells and inoc-
ulation of nude mice showed tumors with less associated
angiogenesis and invasive capacity [16]. Our study com-
pliments these findings in an in vivo model by showing a
statistically significant increase in tumor associated vascu-
lar structures in MIF WT compared to KO mice.
Translocation of protein from the cytoplasm to the
nucleus is seen in many regulatory molecules. Proteins
reported to do so in cancer may interact with transcription
factors important for cell growth, angiogenesis and inva-
sion. Nuclear redistribution of MIF has been seen in
tumor tissues from lung adenocarcinoma patients and
Immunohistochemical staining for MIF in sections from MIF WT control (A), BBN treated mice with bladder cancer at 20  weeks (B) and human specimens from benign (C) and high-grade, invasive TCC (D) Figure 2
Immunohistochemical staining for MIF in sections from MIF WT control (A), BBN treated mice with bladder cancer at 20 
weeks (B) and human specimens from benign (C) and high-grade, invasive TCC (D). Short arrows denote cytoplasmic staining 
in WT control and benign human tissue (A, C) with relatively scant nuclear staining. Long arrows denote cytoplasmic and 
intense nuclear staining in murine and human cancer tissue (B, D).BMC Cancer 2007, 7:135 http://www.biomedcentral.com/1471-2407/7/135
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glioblastoma multiforme tissue [23,24]. Although MIF
was seen in normal lung tissue by IHC, staining was noted
only in the cytoplasm. As in our study, MIF was seen only
in the cytoplasm in normal lung tissue by IHC. In lung
cancer specimens MIF staining was noted to be more
intense and seen in the nuclei of a large portion of the
specimens. Stratification of patient outcome was possible
based on the presence of nuclear staining. However, con-
trary to our findings in mice, nuclear staining portended a
better clinical outcome for lung cancer patients [23]. In
normal brain tissue no cytoplasmic or nuclear staining
was noted for MIF yet brain cancer specimens revealed
nuclear localization of MIF. We have preliminary data
from human bladder cancer specimens showing similar
redistribution of MIF to the nucleus when compared to
benign tissue (Figure 2).
This is the first report of the impact of MIF gene deletion
on the development and progression of bladder cancer.
Our findings are derived from a small pilot study and will
need to be confirmed and expanded in larger studies that
identify the mechanisms of MIF involvement in the pro-
gression to muscle invasion.
Conclusion
MIF KO mice developed consistently lower stage tumors
with less associated angiogenesis in a BBN model of blad-
der cancer. Tumor presence was associated with nuclear
Bladder cancer specimens from MIF WT (A, B) and KO (C, D) animals treated with BBN Figure 3
Bladder cancer specimens from MIF WT (A, B) and KO (C, D) animals treated with BBN. A and C are representative areas of 
tumor with (A) and without (C) muscle invasion. B and D show immunohistochemical staining for vascular structures (arrow-
heads) by PECAM-1 in the same region. Note the marked increase in number of vessels in the WT animal (B) as compared to 
the KO (D).BMC Cancer 2007, 7:135 http://www.biomedcentral.com/1471-2407/7/135
Page 7 of 8
(page number not for citation purposes)
redistribution of MIF. These preliminary data suggest that
MIF plays a role in the progression to muscle invasive dis-
ease.
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